These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier? Terpos E; Trougakos IP; Karalis V; Ntanasis-Stathopoulos I; Sklirou AD; Bagratuni T; Papanagnou ED; Patseas D; Gumeni S; Malandrakis P; Korompoki E; Dimopoulos MA Am J Hematol; 2021 Sep; 96(9):E321-E324. PubMed ID: 34028867 [No Abstract] [Full Text] [Related]
43. Third vaccine boosters and anti-S-IgG levels: A comparison of homologous and heterologous responses and poor immunogenicity in hepatocellular carcinoma. Wang CW; Huang CF; Jang TY; Yeh ML; Liang PC; Wei YJ; Hsu PY; Huang CI; Hsieh MY; Lin YH; Huang JF; Dai CY; Chuang WL; Yu ML Kaohsiung J Med Sci; 2024 May; 40(5):477-488. PubMed ID: 38363080 [TBL] [Abstract][Full Text] [Related]
44. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection. Nemet I; Kliker L; Lustig Y; Zuckerman N; Erster O; Cohen C; Kreiss Y; Alroy-Preis S; Regev-Yochay G; Mendelson E; Mandelboim M N Engl J Med; 2022 Feb; 386(5):492-494. PubMed ID: 34965337 [No Abstract] [Full Text] [Related]
45. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021. Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ; MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654 [TBL] [Abstract][Full Text] [Related]
46. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. Levine-Tiefenbrun M; Yelin I; Alapi H; Katz R; Herzel E; Kuint J; Chodick G; Gazit S; Patalon T; Kishony R Nat Med; 2021 Dec; 27(12):2108-2110. PubMed ID: 34728830 [TBL] [Abstract][Full Text] [Related]
47. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study. Fendler A; Shepherd STC; Au L; Wilkinson KA; Wu M; Byrne F; Cerrone M; Schmitt AM; Joharatnam-Hogan N; Shum B; Tippu Z; Rzeniewicz K; Boos LA; Harvey R; Carlyle E; Edmonds K; Del Rosario L; Sarker S; Lingard K; Mangwende M; Holt L; Ahmod H; Korteweg J; Foley T; Bazin J; Gordon W; Barber T; Emslie-Henry A; Xie W; Gerard CL; Deng D; Wall EC; Agua-Doce A; Namjou S; Caidan S; Gavrielides M; MacRae JI; Kelly G; Peat K; Kelly D; Murra A; Kelly K; O'Flaherty M; Dowdie L; Ash N; Gronthoud F; Shea RL; Gardner G; Murray D; Kinnaird F; Cui W; Pascual J; Rodney S; Mencel J; Curtis O; Stephenson C; Robinson A; Oza B; Farag S; Leslie I; Rogiers A; Iyengar S; Ethell M; Messiou C; Cunningham D; Chau I; Starling N; Turner N; Welsh L; van As N; Jones RL; Droney J; Banerjee S; Tatham KC; O'Brien M; Harrington K; Bhide S; Okines A; Reid A; Young K; Furness AJS; Pickering L; Swanton C; ; Gandhi S; Gamblin S; Bauer DL; Kassiotis G; Kumar S; Yousaf N; Jhanji S; Nicholson E; Howell M; Walker S; Wilkinson RJ; Larkin J; Turajlic S Nat Cancer; 2021 Dec; 2():1321-1337. PubMed ID: 34950880 [TBL] [Abstract][Full Text] [Related]
48. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. Corbett KS; Gagne M; Wagner DA; O' Connell S; Narpala SR; Flebbe DR; Andrew SF; Davis RL; Flynn B; Johnston TS; Stringham CD; Lai L; Valentin D; Van Ry A; Flinchbaugh Z; Werner AP; Moliva JI; Sriparna M; O'Dell S; Schmidt SD; Tucker C; Choi A; Koch M; Bock KW; Minai M; Nagata BM; Alvarado GS; Henry AR; Laboune F; Schramm CA; Zhang Y; Yang ES; Wang L; Choe M; Boyoglu-Barnum S; Wei S; Lamb E; Nurmukhambetova ST; Provost SJ; Donaldson MM; Marquez J; Todd JM; Cook A; Dodson A; Pekosz A; Boritz E; Ploquin A; Doria-Rose N; Pessaint L; Andersen H; Foulds KE; Misasi J; Wu K; Carfi A; Nason MC; Mascola J; Moore IN; Edwards DK; Lewis MG; Suthar MS; Roederer M; McDermott A; Douek DC; Sullivan NJ; Graham BS; Seder RA Science; 2021 Dec; 374(6573):1343-1353. PubMed ID: 34672695 [TBL] [Abstract][Full Text] [Related]
49. Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine. Baldolli A; Fournier A; Verdon R; Michon J Clin Microbiol Infect; 2022 Jun; 28(6):885.e1-885.e5. PubMed ID: 35182759 [TBL] [Abstract][Full Text] [Related]
50. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines. Wang Y EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128 [No Abstract] [Full Text] [Related]
51. "COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment". Munavalli GG; Guthridge R; Knutsen-Larson S; Brodsky A; Matthew E; Landau M Arch Dermatol Res; 2022 Jan; 314(1):1-15. PubMed ID: 33559733 [TBL] [Abstract][Full Text] [Related]
52. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study. Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548 [TBL] [Abstract][Full Text] [Related]
54. Duration of vaccine protection against breakthrough infections during five COVID-19 waves among healthcare workers primarily vaccinated with CoronaVac. Luna-Muschi A; Carmo Borges I; Dos Santos Barboza A; de Faria E; Farrel Cortês M; Santos RB; Costa Silva B; Alves Maia da Silva C; Coelho Rocha E; Reis de Souza V; de Araujo Eliodoro RH; Mendes de Oliveira F; Carolina Mamana A; Miyuki Hidifira A; Nishikawara M; Bertollo Gomes Porto V; Paula B Barboza A; Sampaio V; Mariângela Simão ; Lazari CS; Segurado AC; Kallas EG; Marli C Sartori A; Levin AS; Cerdeira Sabino E; Figueiredo Costa S; Vaccine; 2024 Nov; 42(25):126114. PubMed ID: 39019656 [TBL] [Abstract][Full Text] [Related]
55. Immunogenicity of BNT162b2 vaccine after two and three doses: Correspondence. Daungsupawong H; Wiwanitkit V Semergen; 2024; 50(4):102132. PubMed ID: 38295632 [No Abstract] [Full Text] [Related]
56. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Fendler A; Shepherd STC; Au L; Wilkinson KA; Wu M; Byrne F; Cerrone M; Schmitt AM; Joharatnam-Hogan N; Shum B; Tippu Z; Rzeniewicz K; Boos LA; Harvey R; Carlyle E; Edmonds K; Del Rosario L; Sarker S; Lingard K; Mangwende M; Holt L; Ahmod H; Korteweg J; Foley T; Bazin J; Gordon W; Barber T; Emslie-Henry A; Xie W; Gerard CL; Deng D; Wall EC; Agua-Doce A; Namjou S; Caidan S; Gavrielides M; MacRae JI; Kelly G; Peat K; Kelly D; Murra A; Kelly K; O'Flaherty M; Dowdie L; Ash N; Gronthoud F; Shea RL; Gardner G; Murray D; Kinnaird F; Cui W; Pascual J; Rodney S; Mencel J; Curtis O; Stephenson C; Robinson A; Oza B; Farag S; Leslie I; Rogiers A; Iyengar S; Ethell M; Messiou C; Cunningham D; Chau I; Starling N; Turner N; Welsh L; van As N; Jones RL; Droney J; Banerjee S; Tatham KC; O'Brien M; Harrington K; Bhide S; Okines A; Reid A; Young K; Furness AJS; Pickering L; Swanton C; ; Gandhi S; Gamblin S; Bauer DLV; Kassiotis G; Kumar S; Yousaf N; Jhanji S; Nicholson E; Howell M; Walker S; Wilkinson RJ; Larkin J; Turajlic S; Nat Cancer; 2021 Dec; 2(12):1305-1320. PubMed ID: 35121899 [TBL] [Abstract][Full Text] [Related]
57. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Cohn BA; Cirillo PM; Murphy CC; Krigbaum NY; Wallace AW Science; 2022 Jan; 375(6578):331-336. PubMed ID: 34735261 [TBL] [Abstract][Full Text] [Related]
58. What the Omicron wave is revealing about human immunity. Willyard C Nature; 2022 Feb; 602(7895):22-25. PubMed ID: 35110764 [No Abstract] [Full Text] [Related]
59. A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children. Priddy F; Chalkias S; Essink B; Whatley J; Brosz A; Lee IT; Feng J; Tracy L; Deng W; Zhou W; Zhou H; Dixit A; Schnyder-Ghamloush S; Girard B; de Windt E; Yeakey A; Miller J; Das R; Kuter BJ Expert Rev Vaccines; 2024; 23(1):862-878. PubMed ID: 39234779 [TBL] [Abstract][Full Text] [Related]